Hims argued that the agency ignored the company’s disclosures and misapplied federal law on subscriptions and privacy.
The company plans to offer testosterone replacement therapy, marking its first foray into prescribing controlled substances.
Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the launch of new ...
Stocktwits on MSN
HIMS stock gains as company enters German men’s weight market as investors watch US peptide compounding policy
The new launch builds on the company’s earlier efforts at expanding in Europe, including the acquisition of UK-based health ...
Well, have no fear, telehealth giant Hims is here to capitalize on…er, help address your feelings of inadequacy by offering testosterone replacement therapy service. The company announced Wednesday ...
The plan would apparently temporarily allow specialty pharmacies to compound certain unapproved peptides, including BPC-157.
Hims & Hers Health ( NYSE:HIMS ), the health and wellness platform, launched injectable and oral testosterone replacement therapies for eligible men. Hims & Hers shares rose 0.51% in premarket.
Hims & Hers Health (HIMS) is positioned as a dominant DTC Telehealth platform leveraging GLP-1s to create frictionless, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results